This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.80% per year. These returns cover a period from January 1, 1988 through August 3, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
View All Zacks #1 Ranked Stocks
Zacks News
Are You Looking for a Top Momentum Pick? Why Encompass Health (EHC) is a Great Choice
by Zacks Equity Research
Does Encompass Health (EHC) have what it takes to be a top stock pick for momentum investors? Let's find out.
Can Lower Expenses Save Pediatrix Medical's Q1 Earnings?
by Zacks Equity Research
MD's first-quarter results are likely to reflect declining hospital contract administrative fees.
Encompass Health (EHC) is a Top-Ranked Value Stock: Should You Buy?
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
SRDX Stock Down Following Q2 Earnings Miss, Gross Margin Contracts
by Zacks Equity Research
Despite the strength in Pounce thrombectomy device platforms and strong IVD product sales, Surmodics' second-quarter fiscal 2025 results show weak performance.
OPK Stock Slips Following Q1 Earnings Miss, Gross Margin Expands
by Zacks Equity Research
Despite strength in OPKO Health's revenues from the transfer of intellectual property, the company reports an overall soft first-quarter 2025 performance.
BD Stock Falls in Pre-Market Despite Q2 Earnings Beat, Margins Down
by Zacks Equity Research
BDX's overall topline in the second quarter of fiscal 2025 continues to benefit from strength in its Medical segment and geographic performances.
Humana's Q1 Earnings Beat Estimates on CenterWell Segment Strength
by Zacks Equity Research
HUM's first-quarter results reflect higher primary care revenues and a well-performing Medicare stand-alone PDP business, partly offset by elevated operating costs.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Encompass Health Beats Q1 Earnings Estimates, Ups '25 EPS View
by Zacks Equity Research
EHC's Q1 results benefit on the back of discharge growth and expansion endeavors, partly offset by high operating costs. It currently expects 2025 adjusted EPS from continuing operations within $4.85-$5.10.
Encompass Health Corporation (EHC) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Encompass Health (EHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.